Characterizing Perinatal Treatment Patterns and Outcomes in Myasthenia Gravis
Muscle & Nerve · 2026
DOI: 10.1002/mus.70090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Melanie H Jacobson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Horsham, Pennsylvania, USA. Hauptthemen laut MEDLINE: Myasthenia Gravis, Pregnancy Complications, Pregnancy Outcome, Perinatal Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction/Aims Studies on pregnancy in myasthenia gravis (MG) are limited by small sample sizes or examine a limited number of outcomes. The objective of this study was to estimate the prevalence of perinatal and infant outcomes and characterize perinatal treatment patterns in MG.
Methods
We conducted a retrospective cohort study in Merative MarketScan Commercial Claims and Encounters (CCAE) and two other United States health insurance claims databases. Pregnancies in females aged 18–49 years were identified and maternal and infant records were linked. MG was defined by ≥ 1 inpatient or ≥ 2 outpatient diagnoses within a 365‐day period. The prevalence of six perinatal outcomes was calculated in the MG and total populations. Treatments were summarized by class.
Results
In pregnancies from CCAE between 2000–2023, preeclampsia (10.7% vs. 7.1%), Cesarean section (42.9% vs. 36.7%), preterm birth (18.0% vs. 9.9%), and small for gestational age (4.3% vs. 1.7%) were more frequent among MG ( n = 900) than the age‐adjusted total population ( n = 5,185,726). Lack of treatment for MG was common across the perinatal period: 54.3% were untreated in the 6 months preconception, 61.2% in pregnancy, and 57.8% in the 6 months postpartum. Of those taking acetylcholinesterase inhibitors or corticosteroids in pregnancy, 21.8% and 33.1% had not been taking them before pregnancy, respectively.
Discussion
MG was associated with a greater prevalence of certain perinatal outcomes, occurring in both mother and infant. In parallel, though most patients did not receive treatment in pregnancy those who did showed variation over time, suggesting a potential need for this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Johnson & Johnson, Horsham, Pennsylvania, USA.
- Department of Neurology, Houston Methodist, Houston, Texas, USA.
- Johnson & Johnson, Cambridge, Massachusetts, USA.
- Department of Neurology, Duke University Medical Center, Durham, North Carolina, USA.
ORCID-Profile: Jill Hardin
Zitieren
APA
Jacobson, M. H., Makadia, R., Anderson, A. E. L., Choudhry, Z., Hall, N., Hardin, J., Huang, S., Massey, J. M., Ostropolets, A., Sun, R., Zaha, R., & Krumme, A. A. (2026). Characterizing Perinatal Treatment Patterns and Outcomes in Myasthenia Gravis. Muscle & Nerve. https://doi.org/10.1002/mus.70090
Vancouver
Jacobson MH, Makadia R, Anderson AEL, Choudhry Z, Hall N, Hardin J, et al. Characterizing Perinatal Treatment Patterns and Outcomes in Myasthenia Gravis. Muscle & Nerve. 2026. doi:10.1002/mus.70090
BibTeX
@article{Jacobson2026,
author = {Jacobson, Melanie H and Makadia, Rupa and Anderson, Ashley E L and Choudhry, Zia and Hall, Nathan and Hardin, Jill and Huang, Sicong and Massey, Janice M and Ostropolets, Anna and Sun, Ran and Zaha, Rebecca and Krumme, Alexis A},
title = {Characterizing Perinatal Treatment Patterns and Outcomes in Myasthenia Gravis},
journal = {Muscle & Nerve},
year = {2026},
doi = {10.1002/mus.70090}
}
EUVIMED